Pneumonia Vaccine Market Current Situation and Growth by Top Vendors- J&J, Pfizer, GSK, Merck, Serum Institute of India, AstraZeneca, Sanofi Pasteur | Forecast 2021-2025

Global Pneumonia Vaccine Market Synopsis:

The report covers a forecast and an analysis of the Pneumonia Vaccine Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Pneumonia Vaccine Market along with the impact they have on the demand over the forecast period.

According to the market research study, Pneumonia is disease that causes lung contamination occurring in one or both the lungs caused by bacterial organisms, viruses, or fungi; bacterial pneumonia is the most common in adults. As per the National Center for Immunization and Respiratory Diseases, each year in the United States, more than 250,000 people are hospitalized due to pneumonia and about 50,000 people die from the disease each year in the United States.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/275719 .

Some of the most significant key factors driving the growth of the Global Pneumonia Vaccine Market are rapid growth in the prevalence of pneumococcal diseases amongst the population and the introduction of novel vaccines, growing awareness programs about pneumococcal diseases initiated by the Government.

On the basis of Regional analysis, North America is expected to dominate the overall market, throughout the forecast period. Factors such as the presence of key players and established healthcare infrastructure are the key factors accountable for its large share in the market. APAC is the fastest-growing region due to the high prevalence of Pneumonia infection. The major countries of this region have the highest-burden in the world and hence there is more need for vaccination to prevent the disease.

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Pneumonia Vaccine Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Global Key Players:

1 Pfizer Inc

2 Glaxosmithkline Plc

3 Merck & Co., Inc

4 Sanofi Pasteur

5 Serum Institute of India Pvt. Ltd

6 Johnson & Johnson

7 Astellas Pharma Inc

8 Astrazeneca Plc

9 CSL Limited

10 Emergent Biosolutions and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Pneumonia Vaccine Market Report 2021” @ https://www.businessindustryreports.com/buy-now/275719/single .

Product Type Segmentation

1 Pneumococcal Conjugate Vaccine (PCV13)

2 Pneumococcal Polysaccharide Vaccine (PPSV23)

Industry Segmentation

1 Pneumonia

2 Meningitis

3 Sepsis

International Medical Industry News:

Serum Institute of India (February 15, 2021) - World Health Organisation (WHO) grants Emergency Use Listing (EUL) for the AstraZeneca/Oxford COVID-19 vaccine manufactured by Serum Institute of India - AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.

The authorisation of COVID-19 Vaccine AstraZeneca manufactured by AstraZeneca, and COVISHIELD manufactured by Serum Institute of India (SII), enables global access to the vaccine during the pandemic.

The EUL allows for two doses of the vaccine to be administered at a four to 12-week interval. This regimen was shown in clinical trials to be safe and effective in preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose. The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommended a dosing interval of eight to 12 weeks. In addition, they also recommended use of the vaccine in countries where new variants, including the South African B1.351 variant, are prevalent.

AstraZeneca and SII will now work with the COVAX Facility to begin supplying the vaccine around the world, with the majority going to low and middle-income countries as quickly as possible. In the first half of 2021, it is hoped that more than 300 million doses of the vaccine will be made available to 145 countries through COVAX, pending supply and operational challenges. These doses will be allocated equitably according to the COVAX Allocation Framework.

Pascal Soriot, Chief Executive Officer, said: “Today’s approval endorses that the vaccine can be used to help protect populations across the world, including adults over 65 years and in countries where different variants of the SARS-CoV-2 virus are in circulation. This is a huge step towards ensuring global access to our vaccine and helping us fulfil our public health commitment to broad and equitable access at no profit during the pandemic.”

Adar Poonawalla, Chief Executive Officer, Serum Institute of India, said: “We have been waiting for this final milestone. I am happy and relieved that with the WHO's EUL we will be able to start the deliveries to African and other low and middle-income countries immediately. Countries with a large population must be protected as soon as possible.”

AstraZeneca has committed to making its COVID-19 vaccine available to as many countries as possible and at no profit during the pandemic period. In June 2020, the Company announced a sub-licencing agreement with the SII to manufacture and supply up to one billion doses of the vaccine to low and middle-income countries.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/275719 .

Major Points in Table of Contents:

Global Pneumonia Vaccine Market Report 2021

1 Pneumonia Vaccine Product Definition

2 Global Pneumonia Vaccine Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Pneumonia Vaccine Shipments

2.2 Global Manufacturer Pneumonia Vaccine Business Revenue

2.3 Global Pneumonia Vaccine Market Overview

3 Manufacturer Pneumonia Vaccine Business Introduction

3.1 Pfizer Inc. Pneumonia Vaccine Business Introduction

3.2 Glaxosmithkline Plc. Pneumonia Vaccine Business Introduction

3.3 Merck & Co., Inc. Pneumonia Vaccine Business Introduction

3.4 Sanofi Pasteur Pneumonia Vaccine Business Introduction

3.5 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Business Introduction

3.6 Johnson & Johnson Pneumonia Vaccine Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.